Kadence

Enhancing male sexual performance

Kadence is developing what aims to be the first FDA approved treatment for premature ejaculation. Kadence's drug candidate is inspired by Kanna, a succulent plant native to South Africa with thousands of years of indigenous use.

Under the radar for now - more info soon.

2022

XEIA invests

2024

Kadence completes Phase 1 clinical trial

Kadence completes Phase 1 clinical trial

2026

Kadence initiates Phase 2 clinical trial

Kadence initiates Phase 2 clinical trial

Want more from XEIA?

Stay up to date on Human 3 - the new epoch of health, wellbeing and performance

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! You've been added to our mailing list.
Oops! Something went wrong while submitting the form.
X-disciplinary Exploration, Investment & Acceleration

© 2025 XEIA Venture Partners, LLC